Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation

NCT06106308 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

113

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Colorectal Cancer
CRC
KRAS/NRAS Mutation

Interventions

DRUG: Onvansertib
DRUG: FOLFIRI
DRUG: Bevacizumab
DRUG: FOLFOX

Sponsor

Cardiff Oncology

Collaborators

[object Object]